Rheumatoid arthritis, ankylosing spondylitis or psoriatic arthritis
Conditions
Interventions
Group 1: Treatment with Remsima®-Pen
Sponsors
Celltrion Healthcare Deutschland GmbH
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: - Signed informed consent (data protection) - Male and female outpatient aged =18 years with the further need of treatment of rheumatoid arthritis (RA), ankylosing spondylitis (AS) or psoriatic arthritis (PsA) - Experience with Remsima®-Pen for at least 3 self-injections at first or later re-visit of patient after hand-over of the Remsima®-Pen at the physician site
Exclusion criteria
Exclusion criteria: - Patient <18 years (children and adolescents) - Patient who exhibit contraindications according to SPC (Summary of Product Characteristics) for Remsima® 120 mg or hypersensitivity to any of the ingredients of Remsima® 120 mg is known and therefore treatment with Remsima® 120 mg is not indicated
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary endpoint is defined as percentage of participants that are either "very satisfied (score = 4)" or "satisfied (score = 3)" with the Remsima®-Pen. Single survey. | — |
Secondary
| Measure | Time frame |
|---|---|
| - Percentage of patients that are either "very satisfied" or “satisfied” with quality and understandabilitly of the training materials of the Remsima®-Pen. - Personal experience with the Remsima®-Pen using a patient questionnaire. Single survey. | — |
Countries
Germany
Contacts
Public ContactKirsten Guntermann
Celltrion Healthcare Deutschland GmbH
Outcome results
None listed